BRAF V600 co-testing in thyroid FNA cytology: Short-term experience in a large cancer centre in the UK

Journal of Clinical Pathology

Volumn 67, Issue 8, 2014, Pages 684-689

  Poller, David N ^a   Glaysher, Sharon ^a   Agrawal, Avi ^b   Caldera, Saliya ^b   Kim, Dae ^b   Yiangou, Constantinos ^b  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b Portsmouth General Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; DIAGNOSIS; MOLECULAR PATHOLOGY; SURGERY; THYROID;

BIOPSY, FINE-NEEDLE; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; MALE; PROTO-ONCOGENE PROTEINS B-RAF; THYROID GLAND; THYROID NEOPLASMS;

EID: 84905088830     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202348     Document Type: Article

References (35)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54. (Pubitemid 34716871)
2. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404. (Pubitemid 37452745)
3. Sarne DH. A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab 2012;97:3094-6.
4. Nikiforov YE, Ohori NP. Papillary carcinoma. In: Nikiforov Y, Biddinger PW, Thompson LDR, eds. Diagnostic pathology and molecular genetics of the thyroid: a comprehensive guide for practicing Thyroid pathology. 2nd edn: Lippincott Williams & Wilkins, 2012:183- 246.
5. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:5175-80. (Pubitemid 39391466)
6. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006;65:660-6. (Pubitemid 44583829)
7. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15:136-43. (Pubitemid 44325474)
8. Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006;3:10.
9. Sapio MR, Posca D, Raggioli A, et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007;66:678-83. (Pubitemid 46699541)
10. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-8.
11. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010;95:3693-700.
12. Musholt TJ, Fottner C, Weber MM, et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fi ne-needle aspiration biopsies of thyroid nodules. World J Surg 2010;34:2595-603.
13. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol 2010;118:17-23.
14. Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011;96:658-64.
15. Poller DN, Glaysher S. BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy. Cytopathology 2014;25:155-9.
16. Johnson SJ, Hardy SA, Roberts C, et al. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology. Cytopathology 2014;25:146-54.
17. Guidance on the reporting of thyroid cytology specimens. Secondary Guidance on the reporting of thyroid cytology specimens 2009. http://www.rcpath.org/Resources/RCPath/Migrated%2520Resources/Documents/G/ g089guidanceonthereportingofthyroidcytologyfinal.pdf
18. Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology. Definitions, criteria and explanatory notes. London: Springer, 2010.
19. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000. (Pubitemid 35424092)
20. Collisson EA, De A, Suzuki H, et al. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003;63:5669-73. (Pubitemid 37187459)
21. Cooper WA, Lam DC, O'Toole SA, et al . Molecular biology of lung cancer. J Thorac Dis 2013;5(Suppl 5):S479-S90.
22. Oliveira C, Pinto M, Duval A, et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003;22:9192-6. (Pubitemid 38067995)
23. Guidelines for the Management of Thyroid Cancer. Secondary Guidelines for the Management of Thyroid Cancer 2007. http://www.british-thyroid-association. org/news/Docs/Thyroid-cancer-guidelines-2007.pdf
24. Cooper DS, Doherty GM, Haugen BR, et al.; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
25. British Thyroid Association. Guidelines for the management of Thyroid cancer. (draft) 3rd edn. 2014. http://www.british-thyroid-association.org/ Guidelines/accessed 22.5.14
26. Bergamaschi R, Becouarn G, Ronceray J, et al. Morbidity of thyroid surgery. Am J Surg 1998;176:71-5. (Pubitemid 28340962)
27. Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 2012;97:1905-12.
28. Poller DN, Kandaswamy P. A simplified economic approach to thyroid FNA cytology and surgical intervention in thyroid nodules. J Clin Pathol 2013;66:583-8.
29. Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA 2013;310:535.
30. Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012;60:1052-9.
31. Hodak SP, Rosenthal DS; American Thyroid Association Clinical Affairs C. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid 2013;23:131-4.
32. Montero PH, Ibrahimpasic T, Nixon IJ, et al. Thyroid metastasectomy. J Surg Oncol 2014;109:36-41.
33. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-12. (Pubitemid 37139829)
34. Breeze J, Poller DN, Gibson D, et al. Rapid on-site assessment of specimens by biomedical scientists improves the quality of head and neck fine needle aspiration cytology. Cytopathology 2013. doi:10.1111/cyt.12106
35. Antic T, Taxy JB. Thyroid frozen section: supplementary or unnecessary? Am J Surg Pathol 2013;37:282-6.